In summary, an autologous tumor cell vaccine loaded with a non-lytic NDV expressing IL-7 (i.e., LX/IL-7) provides significant prophylactic and therapeutic benefits by activating tumor-specific cytotoxic T-cell responses. The gene discussed is IL7; the disease is neoplasm.